Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial—PaCa-DD-041 (Eudra-CT 2009-011968-11)

BACKGROUND: Pancreatic cancer is a devastating disease with a 5-year survival rate of 20–25%. As approximately only 20% of patients diagnosed with pancreatic cancer are initially staged as resectable, it is necessary to evaluate new therapeutic approaches. Hence, neoadjuvant (radio)chemotherapy is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Carolin, Distler, Marius, Jentsch, Christina, Blum, Sophia, Folprecht, Gunnar, Zöphel, Klaus, Polster, Heike, Troost, Esther G. C., Abolmaali, Nasreddin, Weitz, Jürgen, Baumann, Michael, Saeger, Hans-Detlev, Grützmann, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801319/
https://www.ncbi.nlm.nih.gov/pubmed/32638040
http://dx.doi.org/10.1007/s00066-020-01654-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801319/
https://www.ncbi.nlm.nih.gov/pubmed/32638040
http://dx.doi.org/10.1007/s00066-020-01654-4

Ejemplares similares